Benlysta is a medicine used as an add\-on treatment in people aged 5 years and older with systemic lupus erythematosus (SLE), a disease in which the immune system (the body’s natural defences) attacks normal cells and tissues, causing inflammation and organ damage. Benlysta is given to people whose disease is still highly active despite standard treatment. Benlysta is also used in adults to treat active lupus nephritis, a manifestation of SLE causing kidney damage. In this case, it is given in combination with different immunosuppressants (medicines that reduce the activity of the immune system). Benlysta contains the active substance belimumab.
Therapeutic Indication
Benlysta is indicated as add\-on therapy in patients aged 5 years and older with active, autoantibody\-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti‑dsDNA and low complement) despite standard therapy. Benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis. Benlysta is indicated as add\-on therapy in adult patients with active, autoantibody\-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti dsDNA and low complement) despite standard therapy.
Therapeutic Area (MeSH)
ATC Code
L04AG04
ATC Item
N/A
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
EMA Name
Benlysta
Medicine Name
Benlysta
Aliases
N/ANo risk management plan link.
